Capstone Therapeutics says prior quarterly EPS figures should no longer be relied upon after share-count error

• Capstone Therapeutics flagged non-reliance on certain previously issued quarterly financial statements due to errors in weighted-average share counts.
• Issue affects basic and diluted net loss per share for quarters ended June 30, 2025, Sept. 30, 2025, and comparative March 31, 2025.
• Audit committee concurred on Aug. 10, 2026; amendments on Form 10-Q/A filed for June 30, 2025, Sept. 30, 2025, and March 31, 2026.
• Restated March 31, 2025 weighted-average shares to 1,555,566 from 5,190,251; net loss per share revised to $(1.56) from $(0.47).
• Management identified a material weakness in internal controls tied to EPS share-count computation; net loss and balance sheet amounts were not affected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027149), on August 12, 2026, and is solely responsible for the information contained therein.